NASDAQ · Healthcare · Biotechnology
Attovia Therapeutics, Inc.
ATTO
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. CEO Tao Fu · Market cap $895.0M.
$20.80
+0.59 · +2.92%
52w hi $24.3252w lo $16.15
Off 52w high 15.8%
76
STRONG
Current InsiderScore
Corp · 90d
11
9 buys · 2 sales
Cong · 90d
0
0 buys · 0 sales
Signals ≥ 60 · 12mo
7
1 strong · 6 notable
Analyst consensus
—
—
Section 01
Recent Form 4 filings
11 filings on file
| Date | Insider | Role | Action | Shares | Price | Value | Score |
|---|---|---|---|---|---|---|---|
| Aug 06 | GOLDMAN SACHS GROUP INC | Buy | 500,000 | $17.00 | +$8.50M | 64 | |
| Aug 06 | Colin Walsh | Buy | 500,000 | $17.00 | +$8.50M | 67 | |
| Aug 06 | venBio Global Strategic Fund IV, L.P. | Buy | 382,352 | $17.00 | +$6.50M | 59 | |
| Aug 06 | Redmile Group, LLC | Buy | 200,000 | $17.00 | +$3.40M | 70 | |
| Aug 06 | Sanofi | Buy | 300,000 | $17.00 | +$5.10M | 73 | |
| Aug 06 | Redmile Group, LLC | Buy | 400,000 | $17.00 | +$6.80M | 76 | |
| Aug 06 | Frazier Life Sciences XI, L.P. | Buy | 588,235 | $17.00 | +$10.00M | 59 | |
| Aug 05 | GOLDMAN SACHS GROUP INC | Sell | 76,418 | $21.04 | −$1.61M | 48 | |
| Aug 05 | GOLDMAN SACHS GROUP INC | Buy | 85,000 | $21.00 | +$1.78M | 68 | |
| Aug 05 | Colin Walsh | Sell | 76,418 | $21.04 | −$1.61M | 51 | |
| Aug 05 | Colin Walsh | Buy | 85,000 | $21.00 | +$1.78M | 71 |
Section 02
Recent STOCK Act disclosures
No disclosures yet
No STOCK Act disclosures on record for this ticker.
Section 03
InsiderScore history
Rolling 12 months · peak score per month
SepOctNovDecJanFebMarAprMayJunJulAug